Literature DB >> 30228888

The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding.

Stephan R Vavricka1,2,3, Henriette Heinrich2,3, Simon Buetikofer1,2, Flavia Breitenmoser1, Emanuel Burri4, Xiaoye Schneider-Yin5, Jasmin Barman-Aksoezen5, Luc Biedermann2, Michael Scharl2, Jonas Zeitz2, Gerhard Rogler2, Benjamin Misselwitz2, Matthias Sauter1,2,3.   

Abstract

BACKGROUND: Faecal calprotectin correlates with histological and clinical activity in inflammatory bowel disease. Gastrointestinal bleeding might also increase faecal calprotectin levels, erroneously implying intestinal inflammation; however, this possibility has not been systematically assessed.
METHODS: Sixteen healthy volunteers without gastrointestinal disease and normal faecal calprotectin baseline values ingested their own blood twice, either by drinking or via nasogastric tube. Quantities of 100 ml and 300 ml blood were ingested in a randomised order, with a 28-day wash-out period. Faecal calprotectin, faecal occult blood test, and the occurrence of melaena were assessed. Faecal calprotectin ≥ 50 µg/g was considered elevated.
RESULTS: Melaena was reported by all healthy volunteers after 300 ml and by 11/15 healthy volunteers (71%) after 100 ml blood ingestion. One day after ingestion of 300 ml blood, 8/16 faecal calprotectin tests were positive compared to 1/16 at baseline (p = 0.016). Faecal calprotectin levels above > 200 µg/g were rarely observed. There was a trend for faecal calprotectin test positivity also after ingestion of 100 ml.
CONCLUSION: Ingestion of blood resulted in an increase in faecal calprotectin-positive tests. Gastrointestinal bleeding should be considered as a potential cause of mild faecal calprotectin elevation > 50 µg/g; however, increased faecal calprotectin above > 250-300 µg/g, the established cut-off for relevant intestinal inflammation in patients with inflammatory bowel disease, is rare.

Entities:  

Keywords:  Calprotectin; Crohn’s disease; gastrointestinal bleeding; inflammatory bowel disease; mucosal inflammation; ulcerative colitis

Year:  2018        PMID: 30228888      PMCID: PMC6137587          DOI: 10.1177/2050640618774416

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  40 in total

1.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

2.  Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin.

Authors:  M Steinbakk; C F Naess-Andresen; E Lingaas; I Dale; P Brandtzaeg; M K Fagerhol
Journal:  Lancet       Date:  1990-09-29       Impact factor: 79.321

Review 3.  Fecal biomarkers in inflammatory bowel disease.

Authors:  Robert N Lopez; Steven T Leach; Daniel A Lemberg; Gilles Duvoisin; Richard B Gearry; Andrew S Day
Journal:  J Gastroenterol Hepatol       Date:  2017-03       Impact factor: 4.029

4.  Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.

Authors:  Petr Ricanek; Stephan Brackmann; Gøri Perminow; Lars G Lyckander; Jon Sponheim; Oyvind Holme; Ole Høie; Andreas Rydning; Morten H Vatn
Journal:  Scand J Gastroenterol       Date:  2011-05-30       Impact factor: 2.423

5.  Clinical remission in Crohn's disease--assessment using faecal 111In granulocyte excretion.

Authors:  S H Saverymuttu
Journal:  Digestion       Date:  1986       Impact factor: 3.216

Review 6.  Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.

Authors:  Taina Sipponen; Kaija-Leena Kolho
Journal:  Scand J Gastroenterol       Date:  2015-01       Impact factor: 2.423

7.  Imaging mass spectrometry for assessing temporal proteomics: analysis of calprotectin in Acinetobacter baumannii pulmonary infection.

Authors:  Jessica L Moore; Kyle W Becker; Joshua J Nicklay; Kelli L Boyd; Eric P Skaar; Richard M Caprioli
Journal:  Proteomics       Date:  2013-07-24       Impact factor: 3.984

8.  Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea.

Authors:  Yogesh M Shastri; Dominik Bergis; Nada Povse; Volker Schäfer; Sarika Shastri; Martin Weindel; Hans Ackermann; Jürgen Stein
Journal:  Am J Med       Date:  2008-12       Impact factor: 4.965

9.  Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study.

Authors:  Michael Manz; Emanuel Burri; Claude Rothen; Nuschin Tchanguizi; Christian Niederberger; Livio Rossi; Christoph Beglinger; Frank Serge Lehmann
Journal:  BMC Gastroenterol       Date:  2012-01-10       Impact factor: 3.067

Review 10.  Update on clinical and research application of fecal biomarkers for gastrointestinal diseases.

Authors:  Imran Siddiqui; Hafsa Majid; Shahab Abid
Journal:  World J Gastrointest Pharmacol Ther       Date:  2017-02-06
View more
  3 in total

1.  United European Gastroenterology Journal making the next step.

Authors:  Joost Ph Drenth
Journal:  United European Gastroenterol J       Date:  2019-01-30       Impact factor: 4.623

2.  International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

Authors:  Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

Review 3.  Calprotectin: from biomarker to biological function.

Authors:  Almina Jukic; Latifa Bakiri; Erwin F Wagner; Herbert Tilg; Timon E Adolph
Journal:  Gut       Date:  2021-06-18       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.